John Sarantopoulos

5.2k citations
143 papers · 3.2k indexed · 1 hit paper · h-index 28

John Sarantopoulos

141 papers receiving 3.1k citations

Hit Papers

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 A...257202120262022202450100150200250

Peers

John Sarantopoulos
Comparison fields: 5 of 113
  • Oncology 1.3k
  • Cancer Research 382
  • Molecular Biology 1.6k
  • Genetics 238
  • Immunology 443
Replace Wijnand Helfrich with:
Wijnand Helfrich Netherlands
Ling Geng United States
Ben Markman Australia
Dominic Fan United States
Maarten L. Janmaat Netherlands
Terence O’Reilly Switzerland
Dmitri Wiederschain United States
Michael Hölzel Germany
James M. Cleary United States
Olivier Dormond Switzerland
John Sarantopoulos relative to Wijnand Helfrich Netherlands Wijnand Helfrich's profile →
Citations per field
00.5×1.5×2.2×
Wijnand Helfrich · 1×
Citations per year

Countries citing papers authored by John Sarantopoulos

Since Specialization
Citations

This map shows the geographic impact of John Sarantopoulos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Sarantopoulos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Sarantopoulos more than expected).

Fields of papers citing papers by John Sarantopoulos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Sarantopoulos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Sarantopoulos. The network helps show where John Sarantopoulos may publish in the future.

Co-authorship network

The 25 scholars most cited alongside John Sarantopoulos, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John Sarantopoulos Line = papers co-authored together John Sarantopoulos links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20251
2 202218
3
Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumorsbreakdown →
2021257
4 202120
5 202049
6 20201
7 201947
8 201768
9 20176
10 2015139
11 2014187
12 201424
13 2014241
14 20143
15 20148
16 201230
17 201270
18 201135
19
A phase I and pharmacokinetic study of a CanAg-targeted immunoconjugate, HuC242-DM4, in patients with CanAg-expressing solid tumors
20072
20
A phase I and pharmacokinetic (PK) study of vinorelbine liposomes injection in patients with advanced solid tumors, non-Hodgkin’s lymphoma, and Hodgkin’s disease
20071

About John Sarantopoulos

John Sarantopoulos is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 143 papers that have together received 3.2k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (37 papers), Cancer, Hypoxia, and Metabolism (20 papers), Lung Cancer Treatments and Mutations (18 papers), Colorectal Cancer Treatments and Studies (16 papers), Radiopharmaceutical Chemistry and Applications (14 papers), Pancreatic and Hepatic Oncology Research (14 papers), Cancer Genomics and Diagnostics (12 papers) and Microtubule and mitosis dynamics (11 papers). The work is most often cited by research in Oncology (1.3k citations), Cancer Research (382 citations) and Molecular Biology (1.6k citations). John Sarantopoulos has collaborated with scholars based in United States, Japan and Switzerland. Frequent co-authors include Devalingam Mahalingam, Alain C. Mita, Monica Mita, Anthony W. Tolcher, Tyler J. Curiel, Kamalesh K. Sankhala, Francis J. Giles, Jordi Rodón, Chia‐Chi Lin and Andrew Brenner. Their work appears in journals such as Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, Molecular Cancer Therapeutics, Clinical Cancer Research and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026